Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sargramostim + zidovudine
- Development stage
- Phase 2
- Lead developer
- Partner Therapeutics
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
Sargramostim + zidovudine is a combination of two pharmaceutical agents: sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), and zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI). Sargramostim stimulates the production and function of white blood cells, specifically neutrophils, macrophages, and eosinophils, thereby supporting immune function. Zidovudine inhibits the replication of human immunodeficiency virus (HIV) by preventing viral RNA from being converted into DNA, essential for viral replication. This combination may be explored for synergistically enhancing immune function in the context of HIV therapy, leveraging sargramostim's myeloid-stimulating effects together with the antiviral action of zidovudine.
02
Targets
CSF2RB (Cytokine receptor common subunit beta)CSF2RA (Granulocyte-macrophage colony-stimulating factor receptor subunit alpha)Human immunodeficiency virus type 1 reverse transcriptaseIL3RA (Interleukin 3 Receptor)SDC2 (Syndecan-2)
Beyond the preview
Go deeper on sargramostim + zidovudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sargramostim + zidovudine.